key: cord-0734573-j71ceuhw authors: Dulovic, A.; Kessel, B.; Harries, M.; Becker, M.; Ortmann, J.; Griesbaum, J.; Juengling, J.; Junker, D.; Hernandez, P.; Gornyk, D.; Gloeckner, S.; Melhorn, V.; Castell, S.; Heise, J.-K.; Kemmling, Y.; Tonn, T.; Frank, K.; Illig, T.; Klopp, N.; Warikoo, N.; Rath, A.; Suckel, C.; Marzian, A. U.; Grupe, N.; Kaiser, P. D.; Traenkle, B.; Rothbauer, U.; Kerrinnes, T.; Krause, G.; Lange, B.; Schneiderhan-Marra, N.; Strengert, M. title: Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany date: 2021-12-05 journal: nan DOI: 10.1101/2021.12.01.21266960 sha: 7854bce68d9c53477c59c47b21df6405fe13c79b doc_id: 734573 cord_uid: j71ceuhw Background While SARS-CoV-2 vaccinations were successful in decreasing COVID-19 caseloads, recent increases in SARS-CoV-2 infections have led to questions about duration and quality of the subsequent immune response. While numerous studies have been published on immune responses triggered by vaccination, these often focused on the initial peak response generated in specific population subgroups (e.g. healthcare workers or immunocompromised individuals) and have often only examined the effects of one or two different immunisation schemes. Methods and Findings We analysed serum samples from participants of a large German seroprevalence study (MuSPAD) who had received all available vaccines and dose schedules (mRNA-1273, BNT162b2, AZD1222, Ad26.CoV2S.2 or a combination of AZD1222 plus either mRNA-1273 or BNT162b2). Antibody titers against various SARS-CoV-2 antigens and ACE2 binding inhibition against SARS-CoV-2 wild-type and the Alpha, Beta, Gamma and Delta variants of concern were analysed using a previously published multiplex immunoassay MULTICOV-AB and an ACE2-RBD competition assay. Among the different vaccines and their dosing regimens, homologous mRNA-based or heterologous prime-boost vaccination produced significantly higher antibody responses than vector-based homologous vaccination. Ad26.CoV2S.2 performance was significantly reduced, even compared to AZD1222, with 91.67% of samples being considered non-responsive forACE2 binding inhibition. mRNA-based vaccination induced a higher ratio of RBD- and S1-targeting antibodies than vector-based vaccination, which resulted in an increased proportion of S2-targeting antibodies. Previously infected individuals had a robust immune response once vaccinated, regardless of which vaccine they received. When examining antibody kinetics post-vaccination after homologous immunisation regimens, both titers and ACE2 binding inhibition peaked approximately 28 days post-vaccination and then decreased as time increased. Conclusions As one of the first and largest population-based studies to examine vaccine responses for all currently available immunisation schemes in Germany, we found that homologous mRNA or heterologous vaccination elicited the highest immune responses. The high percentage of non-responders for Ad26.CoV2.S requires further investigation and suggests that a booster dose with an mRNA-based vaccine may be necessary. The high responses seen in recovered and vaccinated individuals could aid future dose allocation, should shortages arise for certain manufacturers. Given the role of RBD- and S1-specific antibodies in neutralising SARS-CoV-2, their relative over-representation after mRNA vaccination may explain why mRNA vaccines have an increased efficacy compared to vector-based formulations. Further investigation on these differences will be of particular interest for vaccine development and efficacy, especially for the next-generation of vector-based vaccines. In response to the global SARS-CoV-2 pandemic, multiple vaccines have been developed, tested and 75 licensed for use within record time (1-4). As vaccination coverage became more widespread at the 76 beginning of 2021, countries experienced a reduction in SARS-CoV-2 infections (5, 6), although case 77 numbers have again begun to increase in recent months due to spread among and by unvaccinated 78 individuals (7) as well as longevity-related reductions in vaccine protection (8-11). Although a 79 measurable correlate of protection that either prevents SARS-CoV-2 infection or limits COVID-19 80 disease progression is not yet defined, sufficient levels of neutralizing antibodies are assumed to be a 81 key element (12, 13). As in most other countries, the German national vaccination strategy (until June 82 7 th 2021) was based on prioritization by occupation, underlying medical conditions or advanced age. 83 Currently, 56.8 million German residents are reported to be completely vaccinated (68.3% coverage), 84 with a further 2.4 million having so far received one dose. The majority of doses administered based on 85 delivery numbers in Germany are BNT162b2 from Pfizer (77.0%), followed by Astra Zeneca AZD1222 86 (11.3%), Moderna's mRNA-1273 (8.7%) and Janssen's single-shot Ad26.CoV2.S (3.0%; 87 impfdashboard.de and rki.de as of November 25 th 2021). However, based on a lack of efficacy data from 88 phase III clinical trials, the German Standing Committee on Vaccination (STIKO) recommended 89 AZD1222 only for use in those below the age of 60. Following reports of moderate to severe 90 thrombocytopenia and atypical thrombosis cases after AZD1222 vaccination in spring 2021 (14-16), 91 temporary suspensions and eligibility restrictions were not only enacted in Germany (on March 15 th 92 2021) but in 12 other EU member states (17). Administration of AZD1222 was resumed by the 1 st of 93 April 2021 in Germany, however only for those above the age of 60 or after an individual risk analysis. 94 Individuals who had received a first dose of AZD1222 and were below the age of 60 were instead offered 95 a mRNA-based vaccine as second dose which resulted in a heterologous prime-boost vaccination 96 scheme (18). Although these "mix and match" approaches were not covered by the initial licensing 97 terms, it has by now been shown that they result in a more robust humoral and cell-mediated immune 98 response compared to the homologous AZD1222 immunisation (19, 20) . While multiple studies have 99 so far investigated vaccine-induced responses, predominantly in at-risk groups such as dialysis or 100 transplant recipients (21, 22), groups with increased exposure risk such as health care workers (23-25) 101 or as part of the initial clinical efficacy trials which in general enrol healthier than average populations 102 (26), we report immunological vaccination response data from the general adult population. By using 103 samples from a population-based seroprevalence study (MuSPAD), which assessed SARS-CoV-2 104 seroprevalence from July 2020 to August 2021 in eight regions in Germany (27), we examined the 105 dynamics of vaccine-induced humoral responses using MULTICOV-AB (28) and an ACE2-RBD 106 competition assay (29) to analyse ACE2 binding inhibition. 107 Vaccination responses were analysed in participants of the Multi-local and serial cross-110 sectional prevalence study on antibodies against SARS-CoV-2 in Germany (MuSPAD) study, a 111 nationwide population-based SARS-CoV-2 seroprevalence study (27) from July 2020 to August 2021. 112 The study was approved by the Ethics Committee of the Hannover Medical School (9086_BO_S_2020). 113 MuSPAD participants were recruited by age-and gender-stratified random sampling based on records 114 from the respective local residents' registration offices. Study locations in eight regions across Germany 115 were selected in spring 2020 based on differing epidemic activity at that time. In addition to the 116 successive cross-sectional study design, certain study locations were sampled longitudinally within a 3-117 4 month interval. At the study centre, following written informed consent, all eligible participants (>18 118 years) were subject to a standardised computer-based interview using the digital health tool PIA 119 (Prospective Monitoring and Management-App) to gather basic sociodemographic data, information on 120 pre-existing medical conditions including a previously confirmed SARS-CoV-2 infection or a SARS-121 CoV-2 vaccination, once it became available in Germany in late December 2020. Information about 122 SARS-CoV-2 infections or vaccinations are self-reported. After serum was obtained by venipuncture 123 from a serum gel S-Monovette (Sarstedt), samples were aliquoted in Matrix 2D Barcoded Screw Top 124 Tubes (Thermo Scientific) at the Institute of Transfusion Medicine and Immunohematology and frozen 125 at -20°C before being transported on dry ice to the Hannover Unified Biobank (Germany). After 126 registration and quality control, one serum aliquot was shipped to the Natural and Medical Sciences 127 Institute (Reutlingen, Germany) where they were stored at -80°C until analysis. 128 Our study contains a total of 1821 samples from 1731 MuSPAD participants which were divided into 130 three subgroups to examine different aspects of the vaccine-induced humoral response. Based on our 131 inclusion criteria, individual samples can be part of several subgroups. 132 1. Individuals who received a homologous or heterologous full two-dose vaccination with AZD1222, 133 BNT162b2 and mRNA-1273 or the one-dose vaccine Ad26.CoV2.S with a blood sample taken at 134 least 7 days but no more than 65 days post the last vaccination (hereon referred to as "mix and match 135 sample cohort") 136 2. Individuals who donated one blood sample following a two-dose homologous vaccination with 137 BNT162b2 or mRNA-1273 within the defined time frames of day 5 to 12, day 26 to 30, day 54 to 138 58, day 94 to 103, day 129 to 146 or day 176 to 203 after the second dose to monitor antibody kinetics 139 (hereon referred to as "time point sample cohort") 140 3. Individuals with paired blood samples taken at two separate successive time points where the first 141 sample had to be taken a minimum of seven days after the second homologous dose of BNT162b2 142 (hereon referred to as "longitudinal sample cohort"). All samples originated from the following locations where the MUSPAD study had previously been 144 scheduled to take place and were collected from January-August 2021: Aachen (Städteregion), 145 Magdeburg (Stadtkreis), Osnabrück (Stadt-und Landkreis), Chemnitz (Stadtkreis) or Landkreis 146 Vorpommern-Greifswald. A flow chart to illustrate sample selection form the entire MuSPAD cohort 147 can be found in Fig. S1 . Basic sociodemographic information and details of comorbidities (hypertension, 148 cardiovascular disease, diabetes, lung disease, immunosuppression, cancer) for each group are provided 149 in more detail in Table 1 and Table S1 . Apart from the homologous BNT162b2 samples which are part 150 of our mix and match sample cohort, the maximum available sample number meeting the specified 151 criteria in groups 1-3 was used. For the homologous BNT162b2 vaccination samples within our mix and 152 match sample cohort, we applied a random selection from the entire available sample pool of BNT162b2 153 vaccinees who took part in the MuSPAD study to select 771 sera. Individuals with a previous SARS-154 CoV-2 infection either defined by a positive SARS-CoV-2 PCR or antigen test result, or a nucleocapsid 155 IgG normalisation ratio above 1 are listed separately (hereon referred to as "recovered") within the mix 156 and match sample cohort. Additional sample eligibility criteria were having a complete vaccination 157 record (manufacturer and vaccination dates) and information on age and gender as part of the 158 participant's metadata. 159 Vaccine-induced humoral responses were analysed using MULTICOV-AB (28), a previously published 161 multiplex immunoassay that includes both antigens of SARS-CoV-2 (e.g. Spike, Receptor Binding 162 Domain (RBD), S1 domain, S2 domain and nucleocapsid) and the endemic coronaviruses (OC43, 163 HKU1, NL63 and 229E). Samples were processed using an automated platform on a Beckman Coulter 164 i7 pipetting robot as previously described (30). Briefly, samples were thawed at room temperature, 165 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266960 doi: medRxiv preprint vortexed and then centrifuged at 2000 g for 3 mins to pellet any cell debris within the sample. Samples 166 were then opened using a LabElite DeCapper SL (Hamilton Company). Opened sample matrix racks 167 were then loaded into the pipetting robot, where the sample was diluted 1:200 in assay buffer, before 168 being combined in a 384-well plate and mixed 1:1 with 1x bead mix (see Table S2 for antigen panel), 169 resulting in a final dilution of 1:400. Samples were then incubated in a Thermomixer (Eppendorf) for 2 170 h at 1400 rpm, 20°C, in darkness. Following this initial incubation, samples were washed to remove 171 unbound antibodies using an automated magnetic plate washer (Biotek). Bound IgG was detected by 172 adding R-phycoerythrin labelled goat-anti-human IgG (3 µg/mL; #109-116-098, Jackson 173 Immunoresearch Labs) and incubating for a further 45 mins at 1400 rpm, 20°C, in darkness. Following 174 a further washing step, beads were resuspended in 100 µl of wash buffer, shaken for 1 min at 1400 rpm 175 and then measured once on a FLEXMAP 3D instrument (Luminex Corporation) using the following Gamma, Delta VoCs (Table S3) , resulting in a final dilution of 1:400. Samples were then incubated in 187 a Thermomixer for 2 hours at 1400 rpm, 20°C, in darkness. Following this initial incubation, samples 188 were washed to remove unbound ACE2 using an automated magnetic plate washer. ACE2 was detected 189 using R-phycoerythrin labelled streptavidin (2 µg/mL, #SAPE-001, Moss) by incubating the bead-190 sample mix for a further 45 mins at 1400 rpm, 20°C, in darkness. Following a further washing step, 191 beads were resuspended in 100 µl of wash buffer, shaken for 1 min at 1400 rpm and then measured once 192 on a FLEXMAP 3D instrument using the following settings: Timeout 100 sec, Gate 7500-15000, 193 Reporter Gain: Standard PMT, 40 events. As controls, 12 blank wells, 10 wells with 150 ng/mL ACE2 194 alone and 10 wells with an ACE2 QC sample were included. ACE2 binding inhibition was calculated 195 as percentage ACE2 inhibition as in (29) with 100% indicating maximum ACE2 binding inhibition and 196 0% no ACE2 binding inhibition. Samples with an ACE2 binding inhibition less than 20% are classified 197 as non-responders (29). 198 Initial results collation and matching to metadata was done in Excel 2016 and R 4.1.0 (32). For pair-wise comparisons of titres and ACE2 binding inhibition between vaccination schemes within 201 our mix and max sample cohort, we used a two-sided is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; a binary indicator based on low sample numbers). The model further included a random effect defined 213 by the variable "plate number" to account for dependencies due to the measurement procedure, and 214 allowed for heteroscedastic variances for younger (<=70) and older (>70) ages and vaccination types. REML estimation was implemented using the lme function (nlme library (35)). Statistical testing was 216 based on the asymptotic normality of the estimates. As part of a sensitivity analysis, we extended the 217 model with interaction terms between each confounder and the time post-vaccination, allowing for 218 possibly differing effects in the peak (7-27 days) and plateau (28-65 days) period after the last 219 vaccination. Since the effects of the considered covariates were allowed to differ between the 220 vaccination schemes, we analysed only four vaccination schemes (BNT162b2/BNT162b2, mRNA-221 1273/mRNA-1273, AZD1222/BNT162b2, AZD1222/AZD1222) with a sufficient sample size in the 222 mix and match study cohort. Four individuals with BNT162b2/BNT162b2 vaccination with missing 223 comorbidity metadata were excluded from this analysis. The described statistical comparison of 224 vaccination schemes within the mix and max cohort was performed after the exclusion of recovered 225 individuals. To assess the impact of a previous SARS-CoV-2 infection on RBD antibody titres and wild-226 type ACE2 binding inhibition among the different vaccination schemes, we also used a two-sided 227 Brunner-Munzel test. To generate a heat map for comparing antigen-specific antibodies formation across different vaccination 229 schemes within the mix and max sample cohort, normalised antibody responses were initially scaled 230 using the function "z-score", before being plotted as a heat map. To evaluate longitudinal changes in 231 antibody response and ACE2 binding inhibition within our longitudinal sample cohort, changes from 232 T1 to T2 were calculated using log2 fold change. Any increase in titre or binding is represented by a 233 positive value, while decreases in titre or binding are represented by negative values. 234 Data visualisation was done in RStudio (Version 1.2.5001 running R version 3.6.1). Additional packages 235 "gplots" (34) and "beeswarm" (35) were used for specific displays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation 244 of the manuscript. 245 First, we examined differences in humoral responses between individuals who received homologous or 247 heterologous immunisation schemes within our mix and match sample cohort where vaccine dose 248 distribution is similar to the German vaccine coverage. Using MULTICOV-AB, we compared 249 vaccination-induced antibody titres generated against the full-length Spike trimer, RBD, S1 and S2 Ad26.CoV2.S 10.14) than vector-based ones (Fig. 1) . When comparing between the two vector-based 255 vaccinations, the two-dose immunisation with AZD1222 resulted in higher titres than the one-dose 256 Ad26.CoV2.S from Janssen. For mRNA vaccines, Moderna's mRNA-1273 produced a significantly 257 higher response than Pfizer's BNT162b2 (p-values <0.001, Table S5 ). Heterologous dose vaccination 258 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; schemes resulted in comparable titres (for Spike and RBD) as homologous mRNA-vaccinated regimens 259 among our study group independent of the origin of the second dose (Spike normalised MFI 260 AZD/mRNA-1273 13.59, AZD/BNT162b2 13.27, RBD normalised MFI AZD/mRNA-1273 28.17, 261 AZD/BNT162b2 25.93). Heterologous titres were in addition significantly higher than those after a 262 homologous AZD1222 two-dose immunisation (p-values <0.001, Table S5 ). In line with their lower 263 titres, serological non-responder rate (defined as a Signal to Cutoff ratio (S/CO) below 1 for either Spike 264 or RBD) was highest for vector-based homologous vaccination schemes ( Table 2) . 265 As multiplex-based serology tests such as MULTICOV-AB offer the unique opportunity for in-depth 266 profiling of polyclonal antibody reactivity towards multiple viral antigens, we then assessed differences 267 in antibody specificities between the different vaccines. Within the mix and match sample cohort, we 268 observed that mRNA-based SARS-CoV-2 vaccinations resulted in reduced S2-specific antibody titres 269 compared to vector-based ones (Fig. 1) . To investigate this unequal antibody distribution further, we 270 initially scaled titres for each individual antigen (Fig. 2) , and found that while Spike, RBD, S1 titres 271 were low for both AZD1222 and Ad26.CoV2.S, S2-specific titres were considerably higher than 272 expected. We then calculated proportional ratios between antigens ( This over-representation of S1-targeting antibodies following mRNA vaccination, was also present in 277 those who received a heterologous dose schedule (AZD1222-mRNA-1273 47.60-fold, AZD1222-278 BNT162b2 65.06-fold). 279 Having determined that mRNA-vaccines produce a significantly higher proportion of RBD and S1 280 antibodies, we next investigated their ACE2 binding inhibition as these antigens are predominantly 281 responsible for antibody-mediated virus neutralization (12, 13). For this, we used a previously published 282 RBD-ACE2 competition assay (21, 29), which detects neutralizing antibody activity only and is 283 comparable to classical viral neutralization assays (9, 29). As expected, homologous mRNA vaccination 284 resulted in higher ACE2 binding inhibition than homologous vector-based vaccination (median ACE2 285 binding inhibition mRNA-1273 0.93, BNT162b2 0.80, AZD1222 0.39, Ad26.CoV2.S 0.03, Fig. 3 ). 286 Neutralizing antibodies generated following vaccination with Ad26.CoV2.S resulted in minimal ACE2 287 binding inhibition, with only 8.3% being classified as responders (29). As variants of concern now 288 comprise the majority of infections globally (36), we also assessed ACE2 binding inhibition against the 289 Alpha, Beta, Gamma and Delta SARS-CoV-2 VoC strains. ACE2 binding inhibition was most similar 290 to wild-type for the Alpha variant, followed by Delta whereas Beta and Gamma variants had the largest 291 reductions in ACE2 binding inhibition (Fig. S2) . 292 Due to the range of responses recorded for each dose combination and likely differences in population 293 characteristics as a result of changing vaccine recommendations, we examined whether confounders 294 (sampling time post-vaccination (ΔT), age, gender or comorbidities) were instead responsible. To 295 analyse impact of ΔT, we separated samples into 7 to 27 days post-final dose to capture peak response 296 and 28 to 65 days post-final dose to capture plateau response (Fig. 4) . While there was a reduction in 297 median response for samples from individuals collected within the plateau phase, the pattern between 298 the vaccines remained consistent. While increasing age did result in small reductions in ACE2 binding 299 inhibition (only significant for BNT162b2, p<0.001), the vaccine dosing scheme received had a 300 substantially larger effect, with the eldest age group (>79) of homologous mRNA vaccine recipients still 301 having increased IgG titres and ACE2 inhibition capacities than the youngest (26 to 45) AZD1222 302 recipients (Fig. 4) . Regression modelling for ACE2 binding inhibition against wild-type confirmed the 303 decrease of ACE2 binding inhibition with time post-vaccination for all vaccination types except 304 homologous AZD1222 (Table S4A) . While age did not cause a significant decrease for homologous 305 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; AZD1222, this may have been due to the low number of samples at both ends of the age range within 306 our cohort. For mRNA-1273, while age did result in a significant decrease during the peak period 307 (p=0.029), this was not present within the plateau phase (p=0.615). For homologous BNT162b2 308 vaccination, male sex seemed to be associated with a decreased ACE2 binding inhibition, although the 309 same was not true for mRNA-1273. Similar patterns were observed for the ACE2 binding inhibition 310 against Alpha, Beta, Gamma and Delta VoCs (Table S4B-E) . As we observed serological non-311 responders within our mix and match study cohort, we systematically evaluated their distribution among 312 the different immunisation schemes (Table 2) . Overall, vector-based homologous vaccination (2.78%) 313 resulted in a higher proportion of non-responders than homologous mRNA-based vaccination (0.89%). 314 Neither age nor gender was a determining factor in being a non-responder. 315 As our population-based cohort also contained individuals who had been previously infected and then 316 vaccinated, we examined what effect this had upon their vaccine-induced response. As previously 317 observed (37), recovered and then vaccinated individuals developed high levels of IgG with strong 318 ACE2 binding inhibition (Fig. 5 Fig. 3) . 323 Having determined that mRNA-based vaccination resulted in an increased humoral response, we 324 evaluated lifespan and antibody response kinetics using our time point sample cohort which were 325 selected to mimic key response periods for antibody-producing B-cell activity such as expansion, peak 326 and plateau phase after a complete vaccination scheme. Vaccine-induced titres and ACE2 binding 327 inhibition both initially increased, peaked during the second time point (26 to 30 days post-second dose), 328 and then decreased linearly as time increased (Fig. 6) . ACE2 binding inhibition followed the same 329 pattern of decrease as time increased. In contrast to antibody levels, the percentage of non-responders 330 showed however a trend for increased decline already from time point 94 to 103 days post-second 331 vaccination onwards for BNT162b2, with 22.22% of samples considered as non-responders at 176-203 332 days post-second vaccination ( Table 2) . As already observed in Figure 1 directly compare changes in titre and activity from the first sampling to the second sampling. While 338 these samples had a variable initial ΔT post-full vaccination (7-63 days), the sampling intervals between 339 first and second donation were more comparable (114-163 days). Overall, titres decreased (median RBD 340 68%) between their first and second sampling (Fig. 7) . Among the different SARS-CoV-2 antigens, 341 RBD and S1 antibodies had the largest decrease, while Spike Trimer and S2 had the smallest. This 342 reduction in titre was reflected in ACE2 binding inhibition which also reduced substantially from the 343 first to second sampling (median 32%). ACE2 binding inhibition was also clearly decreased for all VoC 344 RBDs (Alpha 36%, Beta 30%, Gamma 29%, Delta 38%). 345 We report both significant and substantial differences in humoral responses generated by the different 347 vaccines and dose regimens currently available in Germany, with homologous mRNA or combined 348 heterologous vector and mRNA vaccination approaches inducing significantly higher titres and ACE2 349 binding inhibition compared to homologous vector-based vaccination schemes. This expands on results 350 from on-going randomised and observational trials such as the ComCoV (38) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266960 doi: medRxiv preprint regimens, we identified like others, that mRNA-1273 resulted in higher antibody titres and ACE2 353 binding inhibition than BNT162b2 (37, 41). While we have used an ACE2-RBD competition assay to 354 measure ACE2 binding inhibition as opposed to classic virus neutralization assays, this assay analyses 355 neutralizing antibodies as seen by its similar performance to VNT (9, 29). ACE2 inhibition assays 356 instead of a VNT have also already been used successfully by other groups to determine neutralizing 357 antibody activity (42). Methodically, MULTICOV-AB and the ACE2-RBD competition assay are also 358 complementary and are measured using a single initial sample dilution which further reduces variability 359 between their results. As expected, titres and ACE2 binding inhibition for AZD1222 were reduced 360 compared to mRNA-based vaccination (40). By multiplex-based antibody profiling, we were able to 361 investigate these differences and determine that vector and mRNA-based vaccines induced a distinct 362 pattern of Spike subdomain-targeted antibodies. While vector-based formulations result in a 363 significantly larger proportion of S2-domain antibodies, RBD-and S1-domain antibodies dominated in 364 mRNA vaccines. While these observations require further detailed investigation, the relative over-365 representation of RBD-and S1-targeting antibodies within mRNA vaccines is particularly intriguing as 366 these two antigens comprise the majority of neutralizing antibody activity (13). Despite the lack of a 367 clearly defined correlation of vaccine efficacy and neutralizing antibody levels, it appears logical that 368 increased antibody levels specific to virus protein-mediating cell attachment could result in enhanced 369 levels of protection from infection and contribute to observed differences in levels of vaccine efficacy 370 and effectiveness (2, 43, 44). Interestingly, a series of modelling studies have now linked levels of 371 neutralizing antibodies to vaccine efficacy (12, 45). 372 An additional finding of our study requiring further investigation is the relatively poor performance of 373 Ad26.CoV2.S, particularly for induction of neutralizing antibodies for both SARS-CoV-2 wild-type and 374 VoC RBDs. While some studies have reported sufficient levels of neutralizing activity after vaccination 375 with Ad26.CoV2.S (4), others identified minimal neutralizing activity, particularly when compared to 376 other COVID-19 vaccines from Pfizer or Moderna (41). The relatively poor performance of 377 Ad26.CoV2.S in inducing an antibody response has also been identified by researchers studying other 378 bodily fluids (e.g. breast milk), who found that Ad26.CoV2.S produced significantly fewer IgA 379 antibodies than BNT162b2 or mRNA-1273 (46). While our Ad26.CoV2.S sample group size is low 380 (n=29), it is three times larger than a recent study from the manufacturer which reported neutralizing 381 activity against Delta and other VoCs (n=8, (47)). It should be noted that four of the eight individuals 382 within their cohort were reported as being spike seropositive at baseline which is a consistent finding 383 with our cohort, where strong ACE2 binding inhibition was only achieved in those individuals who had 384 been previously infected. Our median time point is however earlier than the reported peak of antibody 385 activity (4, 48). Further independent investigations into the neutralizing activity generated by single-386 dose of Ad26.CoV2.S to clarify those differing results within SARS-CoV-2 naïve individuals are 387 therefore urgently needed. 388 Among confounding variables, we identified like others that age resulted in a general reduction in titre 389 and ACE2 binding inhibition (10, 37, 49), although the vaccine dose scheme received had a more 390 significant effect. While recovered individuals developing high titres and ACE2 binding inhibition once 391 vaccinated has been previously reported (37, 40), we found that these responses were similar among all 392 vaccines and dose schedules. Given that current German guidelines require a six month post-positive 393 PCR waiting period before receiving a first dose, this suggests that such individuals would be suitable 394 for all currently licensed vaccines, assuming they meet pre-existing EMA and STIKO criteria. This 395 ability to use all vaccines and generate a substantial response will be of particular public health 396 importance, given the on-going booster dose administration which could impact availability for some 397 vaccine brands, as happened earlier in 2021. 398 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266960 doi: medRxiv preprint Our results on the longevity of the humoral response post-vaccination is similar to others, in identifying 399 an initial peak from approximately 28 days post-second dose onwards followed by a gradual reduction 400 over time (50). As expected, ACE2 binding inhibition and titre are mostly mirrored in their decline over 401 time. However, the increased numbers of non-responders from BNT162b2-vaccinated individuals from 402 six months after the second vaccine needs further careful monitoring until a precise correlate of 403 protection has been defined. Among the different SARS-CoV-2 antibodies, it is unsurprising that the 404 RBD and S1 underwent the greatest reductions as they had the largest titres to begin with. Between 405 VoCs, we did not identify any apparent differences in ACE2 binding inhibition within the differing 406 vaccines and dose regimens for confounders. Instead, again vaccine or dose regimen received had the 407 largest effect upon ACE2 binding inhibition. The VoCs themselves followed a previously published 408 pattern (9, 21, 51), with the lowest reduction for the Alpha variant, and the highest for the Beta and 409 Gamma variants. It should be stated that we in our analysis of longitudinal samples, there is a wide 410 variety of timeframes post-vaccination, meaning that initial samples are collected both before, during 411 and after the initial peak response at 28 days. While we have then made the assumption that decreases 412 in responses would be linear to the second sampling, this is not the case as some of the early collected 413 samples (e.g. 7 days post-second vaccination) would have initially increased before later decreasing. 414 However, our purpose of this analysis was to measure changes over a larger timeframe (4 months) and 415 the difference in time from first to second sampling, means that all samples should be in the decline 416 phase by their second sampling. 417 Our manuscript has several limitations, namely that we are only measuring antibodies (including 418 neutralizing antibodies) that are present within serum. As previously stated, we have used an ACE2-419 RBD competition assay to measure inhibition of ACE2 binding instead of classical virus neutralization 420 assays, although the results of this assay have already been shown to be similar to VNT and are known 421 to be specific to neutralizing antibody responses only. While neutralizing antibodies themselves are 422 considered a strong correlate for protection (13), other components that are not measured within our 423 assays such as T-cell mediated immunity will also offer protection (52, 53). Our use of serum also means 424 that memory B-cells, which are involved in protection against severe disease progression (54), are 425 equally excluded from our analysis. Our study cohort consists of relatively low sample numbers for both 426 heterologous and Ad26.CoV2.S vaccinations whereas BNT162b2 samples are overrepresented. 427 However, our sample numbers are similar or in the case of Ad26.CoV2.S exceed other previously 428 published work making our study one of the largest independent evaluation studies of this vaccine. Our 429 BNT162b2 sample size mimics dose distribution in Germany where approximately 70% of delivered 430 vaccine doses were from Pfizer. Our study population is also relatively similar in regard to age and 431 gender. 432 Overall, we provide data on the vaccine-induced humoral response for all currently available mRNA-, 433 vector-based and heterologous immunisation regimens in Germany. Within our population-based 434 cohort, mRNA homologous or heterologous vaccination resulted in increased humoral responses. Our 435 multiplex approach identified differences in quantities and ratios of RBD-and S1-targeting antibodies 436 following mRNA homologous or heterologous vaccination. Further investigation into this targeting will 437 be of particular interest to improve vaccine performance particularly for next generation vector-based 438 vaccines. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint NSM, MS, YK, DG, VM, DJ, PDK, BT, UR, TT, KF, NK, TI, TK, AR, CS, AR, AM, NG and 446 contributed resources or were involved in project administration. All authors critically reviewed and 447 approved the final manuscript. 448 NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute 450 at the University of Tübingen is involved in applied research projects as a fee for services with the 451 Luminex Corporation. The other authors declare no competing interest. 452 First and foremost, we would like to thank the MuSPAD participants for their willingness and 454 commitment to make this study possible. We also want to thank all laboratory members and 455 administrative staff at the Institute of Transfusion Medicine and Immunohematology in Plauen for 456 continued excellent technical and organizational support in sample processing. We are grateful to the 457 entire team of BOS112 for running of MuSPAD study sites. We sincerely thank all participating 458 counties, cities and local health care authorities for their support. We thank Astrid Hans and Carina 459 Lützow for administrative assistance. We thank members of the Multiplex Immunoassays Group at the 460 NMI for their assistance in sample arrival and storage. 461 Data is available upon request from the corresponding authors. 463 The other authors declare no competing interests. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266960 doi: medRxiv preprint Fig. 2 . Humoral immune response after mRNA vaccination is skewed towards increased RBD and S1 titres, 630 while vector-based vaccination results in increased S2 antibody levels. Antigen-specific antibody titres measured in the mix and match sample cohort were scaled and centred per antigen. Resulting values greater than 2.5 and smaller than -2.5 were set to these extreme values instead. Samples were is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. (Table S4) . . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table S6 . . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266960 doi: medRxiv preprint Table 2 . Vaccine non-responder rates across study population. MULTICOV-AB non-responders were determined as in (28), with samples that had a signal to cut-off ratio below 722 1 for either the Spike or RBD being considered non-responders. ACE2-RBD non-responders were determined as 723 in (29), with samples that had a ACE2 binding inhibition less than 20% being considered non-responders. Different is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.01.21266960 doi: medRxiv preprint Table 3 . Antigen-specific ratios for different vaccination schemes. Safety and efficacy 467 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 468 randomised controlled trials in Brazil, South Africa, and the UK. The Lancet Efficacy and Safety of the 470 mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of 472 the BNT162b2 mRNA Covid-19 Vaccine Safety and 474 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 uni-muenchen.de/maps Monitoring 481 Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status -13 90. 484 8. Government I. Verified results after receiving the vaccine among the first vaccinated group Diminishing 488 immune responses against variants of concern in dialysis patients four months after SARS-CoV-2 489 mRNA vaccination Dynamics of antibody 491 response to BNT162b2 vaccine after six months: a longitudinal prospective study Evidence for increased 494 breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. 495 Evidence 497 for antibody as a protective correlate for COVID-19 vaccines Neutralizing 499 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. 500 Nature Medicine Antibody-mediated 502 procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia Thrombotic 505 Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Arterial events, venous 508 thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca 509 population based cohort study Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after Durable Humoral and 591 Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination Spike-antibody 594 responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch 595 study) Four 600 SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T 604 cells Adaptive immune 606 determinants of viral clearance and protection in mouse models of SARS-CoV-2 Distinct 609 antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following 610 mRNA vaccination Longitudinal mRNA vaccine response monitoring defines decreases over time Humoral response was assessed by MULTICOV-AB (a, b) and an ACE2-RBD competition assay (c, d) for all 702 samples of the longitudinal sample set at indicated time points post-second dose of a complete BNT162b2 703 vaccination scheme (n=90) or ACE2 binding inhibition (c) towards WT RBD as time post-vaccination increases. The threshold (less than All samples below this threshold are considered non-responsive. SARS-CoV-2 antigen-specific differences 707 in longitudinal humoral response are expressed as log2 fold changes (b). Reduction in ACE2 binding inhibition 708 for RBD of Alpha